Author: Editor

David Ilson, MD from the Memorial Sloan Kettering Cancer Center speaks about the Top 5 ASCO 2021 Abstracts in Gastrointestinal Cancer.Link to Abstract 4000 – ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).https://meetinglibrary.asco.org/record/195933/abstractLink to Abstract LBA4001 – Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.https://meetinglibrary.asco.org/record/195919/abstractLink to Abstract 4002 – First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced…

Howard ‘Jack’ West, MD, Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research at the City of Hope speaks about ASCO 2021 Top 5 Abstracts in Lung Cancer.Link to Abstract 8500- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).https://meetinglibrary.asco.org/record/195950/abstractLink to Abstract 8517 – Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.https://meetinglibrary.asco.org/record/196544/abstractLink to Abstract 9006 – Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell…

Grzegorz S. Nowakowski, MD from the Mayo Clinic speaks about Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma.Link To Study -https://investor.incyte.com/press-releases/press-releases/2021/Incyte-and-MorphoSys-Announce-First-Patient-Dosed-in-Phase-3-frontMIND-Study-Evaluating-Tafasitamab-Combination-as-a-First-Line-Treatment-for-Diffuse-Large-B-Cell-Lymphoma/default.aspxThe first patient in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) versus R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma was dosed today (DLBCL). Tafasitamab is a humanized monoclonal antibody that is used to target the B-cell specific antigen CD19 and activate immune…

Mingxuan Xu, Ph.D., Research Scientist at MD Anderson speaks about the Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.Link to Naing Tool:https://doi.org/10.36401/JIPO-21-X1Link to Article:https://meridian.allenpress.com/innovationsjournals-JIPO/article/4/2/45/465080/Implementation-of-a-Novel-Web-Based-LesionSUMMARY:The first paragraph is an introduction.Biopsy specimens must yield sufficient tumor tissue, and sequential biopsy specimens should sample a clear site, for the optimum utility of molecular characterization by next-generation sequencing (NGS) and greater understanding of the tumor microenvironment with immune correlates study. We created a web-based lesion selection tool (LST) to help with biopsy specimen collection management and monitoring.Methodologies:The LST was used on 88 of the 145 patients, with…

Murat Ak, MD from UPMC speaks about Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.Link to Abstract:https://jitc.bmj.com/content/9/4/e001752Synopsis:Background information:A radiomics-based model for predicting pembrolizumab response in patients with advanced rare cancers is presented.Methodologies:In the report, 57 patients with advanced rare cancers were enrolled in our pembrolizumab phase II clinical trial. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related RECIST were used to assess tumor response (irRECIST). The patients were divided into two groups: 20 with “controlled disease” (stable disease, partial reaction, or full response) and 37 with “progressive disease.” On standard-of-care, pretreatment contrast improved CT…

Drs. Charu Aggarwal and Jack West host dynamic GU oncology specialist Dr. Petros Grivas as they discuss how research, mentorship, and teaching have adapted to digital platforms in the wake of the pandemic.

Timothy Ritter, MD, Senior Medical Director, Department of Research and Education GI Alliance Research speaks about U.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Geniusâ„¢ Intelligent Endoscopy Module.Link to Article:https://news.medtronic.com/2021-04-12-U-S-FDA-Grants-De-Novo-Clearance-for-First-and-Only-Artificial-Intelligence-System-for-Colonoscopy-Medtronic-Launches-GI-Genius-TM-Intelligent-Endoscopy-ModuleIn the United States, the Food and Drug Administration (FDA) approved de novo clearance for the GI GeniusTM intelligent endoscopy module. The GI Genius module is the first and only commercially viable artificial intelligence (AI)-based computer-aided detection (CADe) method for detecting colorectal polyps. The module, which works with every colonoscope video, gives doctors a new tool to combat colorectal cancer, which…

Lenka Kyrych Sadilkova, Ph.D. from SOTIO speaks about the AACR 2021 Poster: SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies.Link to Article:https://sotio.com/news-publications/news/sotio-demonstrates-strong-potential-of-sot102-adc-targeting-claudin-18-2-for-treatment-of-solid-tumors-in-preclinical-studiesIn a virtual poster presentation at the 2021 American Association of Cancer Research (AACR) Annual Meeting, SOTIO, a clinical-stage immuno-oncology firm owned by PPF Group, revealed new preclinical results of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors. The findings, which show that SOT102 has a high propensity for eradicating CLDN18.2-expressing tumor cells in a target-specific manner, serve as proof of concept for both…

Watch our interview with Dr. Howard Soule and Dr. Becky Campbell from the Prostate Cancer Foundation talking about their new Prostate Cancer Patient Guide

Richard T Penson, MD, MRCP, Associate Professor, Medicine, Harvard Medical School, and Clinical Director, Medical Gynecologic Oncology, Massachusetts General Hospital speaks about Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.  ***This was for the ARIEL4, not the ARIEL3 trial.***Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00073-5/fulltext?utm_campaign=update-lanonc&utm_medium=email&_hsmi=126264841&_hsenc=p2ANqtz–fwIwWOX6zOsv0PbKgjP6nwULFQQ0Ki4AbzR_WHMQzikUfgdBumHyS480a720PFN2PlFrg5Etnpp1g8CYURtfM7BzudkH2NW8hgEa9EerZwOWyycY&utm_content=126264841&utm_source=hs_email#%20In SummaryBackground information:In the SOLO2/ENGOT-Ov21 trial, olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was shown to improve progression-free survival compared to placebo in patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum-sensitive and had a BRCA1 or BRCA2…

Dan Sherbenou, MD, Ph.D. from the University of Colorado Medical Campus, Division of Hematology Research, Sherbenou Lab speaks about Older Multiple Myeloma Patients Require Personalized Treatment.Link to Press Release:https://www.waxmancancer.org/about-us/newsroom/press-releases/method-developed-to-treat-multiple-myeloma-patients/Although MM remains an incurable condition, improvements in drug therapies have increased the quality of life over the past 20 years. Older patients, on the other hand, have a lower tolerance for the side effects of the standard three-drug regimen, which is typically given in monthly or annual infusion appointments. As a result, older patients are often undertreated, receiving two-drug regimens with a lower chance of a positive reaction.Dr. Daniel Sherbenou and…

Coya Tapia, MD, Ph.D., Surgical and Molecular Pathologist speaks about Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.Link to Abstract:https://jitc.bmj.com/content/8/1/e000665.longSynopsis:Background: After neoadjuvant treatment, decreased tumor content (TC) in resection specimens is used to assess prognosis. We looked at whether TC measured in biopsy specimens or the change in TC from baseline to treatment can be used to predict reaction in pembrolizumab-treated patients with rare tumors.Methods: A total of 57 tumors (representing 173 baseline and 179 on-treatment biopsies) were analyzed from 57 patients with unusual tumors who were…

Thomas Brown, MD Syapseâ chief medical officer speaks about Syapse Showcases Real-World Mortality Data in American Society of Clinical Oncologyâs JCO-CCI.Link to Press Release:https://www.globenewswire.com/news-release/2021/04/09/2207503/0/en/Syapse-Showcases-Real-World-Mortality-Data-in-American-Society-of-Clinical-Oncology-s-JCO-CCI.htmlThe results of a peer-reviewed report published in JCO Clinical Cancer Informatics (JCO-CCI), an American Society of Clinical Oncology (ASCO) Journal, were revealed today by Syapse®, a pioneering real-world evidence organization accelerating the delivery of precision medicine through the Syapse Learning Health NetworkTM.The study, titled “Validation of a mortality composite score in the real-world setting: overcoming source-specific disparities and biases,” looked at the Syapse Learning Health Network platform’s ability to accurately assess oncology mortality rates, demonstrating that…

Jonathan A. Coleman, MD from Memorial Sloan Kettering Cancer Center speaks about ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (UCM301).Link to Clinical Trials gov:https://clinicaltrials.gov/ct2/show/NCT04620239Brief Synopsis:TOOKAD is being studied in a phase 3 open label, single arm trial for the treatment of Upper Tract Urothelial Carcinoma (UTUC). Patients with low-grade upper tract urothelial carcinoma in the kidney or ureter may be enrolled in the ENLIGHTED trial. The patients will receive TOOKAD (padeliporfin) VTP in two phases: an induction treatment phase and a maintenance treatment process, followed by a 12-month long-term (non-intervention) follow-up phase.Patients who enroll in the…

Connie Lehman, MD, Ph.D., Diagnostic Radiologist, Chief, Breast Imaging Massachusetts General Hospital speaks about These Doctors Are Using AI to Screen for Breast Cancer.Link to Article:https://www.wired.com/story/doctors-using-ai-screen-breast-cancer/?utm_source=STAT+Newsletters&utm_campaign=ba46f08703-MR_COPY_14&utm_medium=email&utm_term=0_8cab1d7961-ba46f08703-150690609CONSTANCE LEHMAN WAS Persuaded TO Adjust THE WAY MASSACHUSETTS GENERAL HOSPITAL SCREENED WOMEN FOR BREAST CANCER After COVID ARRIVED IN MASSACHUSETTS. Owing to concerns about the infection, several people skipped routine checkups and scans. As a result, the Lehman-coordinated center started using an artificial intelligence algorithm to determine who is most likely to contract cancer.According to Lehman, the AI technique has assisted in identifying a number of women who, after being advised to come in…

Eytan M. Stein, MD, Assistant Attending Physician, and Director, Program for Drug Development in Leukemia, Department of Medicine at Memorial Sloan Kettering Cancer Center, and the trial’s principal investigator speaks about Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias.Link to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT04065399?term=AUGMENT-101+SNDX-5613&draw=2&rank=1Link to Article:https://ir.syndax.com/news-releases/news-release-details/syndax-announces-positive-interim-data-demonstrating-robustModified promising results from the Phase 1 dose-escalation section of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias were released today by a clinical-stage…

Matthew Tate, MD, Ph.D., Associate Professor of Neurological Surgery and Neurology – Ken and Ruth Davee Department Northwestern University Feinberg School of Medicine speaks about Surgical Management of Low-grade Glioma.Link to Press Release:https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr.htmlDuring the simulated American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021, AstraZeneca will discuss insights from the Company’s groundbreaking early oncology pipeline through various strategic channels.The next-generation PARP1 selective inhibitor AZD5305, which will be unveiled in five presentations, demonstrates AstraZeneca’s dedication to developing therapies that selectively destroy cancer cells by attacking the mechanism that cells rely on to repair DNA harm. Furthermore, studies…

David Berd, MD Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day.Link to Article:https://www.prnewswire.com/news-releases/biovaxys-and-the-world-ovarian-cancer-coalition-join-forces-for-may-8th-world-ovarian-cancer-day-301272288.htmlBiovaxys, a global pioneer in haptenized antigen vaccines for antiviral and cancer uses, today declared its support for World Ovarian Cancer Day, a major effort of the World Ovarian Cancer Coalition (“the Coalition”), a non-profit organization based in Canada.On May 8th, 2013, a coalition of leading ovarian cancer activists founded World Ovarian Cancer Day to provide a forum for stakeholders to lift their voices in unity in the battle against ovarian cancer. Although the Coalition operates on a variety of…

Scott Loughhead, Ph.D. from SQZ Biotechnologies speaks about AACR 2021Abstract – Peripheral Blood Mononuclear Cells Engineered Via Microfluidic Cell Squeeze® Technology to Generate APCs that Drive Mutant-KRas-Specific CD8+ T Cell Responses Abstract Number: 1524 – targeting KRAS with SQZ APCs, which show preclinical proof-of-concept for potential applicability to multiple KRAS mutations, supporting the SQZ opportunity to rapidly expand into additional tumor types.Link to Press Release:https://www.pharmiweb.com/press-release/2021-03-10/sqz-biotech-to-present-preclinical-data-on-kras-tumor-targets-and-next-generation-sqz-eapcs-at-the-aSQZ eAPCs are designed to take advantage of the SQZ APC platform’s capabilities to generate robust and specific CD8+ T cell activation through efficient MHC-I antigen presentation. The platform takes advantage of the Cell Squeeze® technology’s…

Scott Loughhead, Ph.D. from SQZ Biotechnologies speaks about AACR 2021Abstracts – Clinical Applications Abstract Number: 2626 and Technology Abstract Number: 1525 – preclinical data from SQZ eAPCs utilizing multiple mRNA cargo to potentially expand addressable patient populations and meaningfully increase CD8 T cell response by incorporation of costimulatory molecules and cytokine signaling.Link to Press Releases:https://www.pharmiweb.com/press-release/2021-03-10/sqz-biotech-to-present-preclinical-data-on-kras-tumor-targets-and-next-generation-sqz-eapcs-at-the-aSQZ eAPCs are designed to take advantage of the SQZ APC platform’s capabilities to generate robust and specific CD8+ T cell activation through efficient MHC-I antigen presentation. The platform takes advantage of the Cell Squeeze® technology’s cargo versatility to develop next-generation product candidates that carry multiple…

Dr. Steve Vogl of “Vogl, New York” fame joins hosts Charu Aggarwal and Jack West as they discuss the priorities of patients and general oncologists in practice as new developments are presented, and how telemedicine was adopted in NYC during the pandemic.

Laura van ’t Veer, Ph.D., Co-Leader, Breast Oncology Program and Director, Applied Genomics at UCSF Helen Diller Family Comprehensive Cancer Center and Co-founder and Chief Research Officer at Agendia speaks about 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00007-3/fulltextDetailsAbstractThe MINDACT trial found that patients with high clinical and low genomic risk breast cancer who did not undergo chemotherapy had a 5-year remote metastasis-free survival rate of 947 percent (95 percent CI 9255–962). We present long-term follow-up findings as well…

Alexey Danilov, MD, Ph.D., associate director of the Toni Stephenson Lymphoma Center at City of Hope speaks about the AACR 2021 Abstract – 938 – Pharmacologic targeting Mcl-1 with AZD5991 induces apoptosis, suppresses mitochondrial respiration, and overcomes ibrutinib resistance in non-Hodgkin lymphoma cells.Link to Abstract:https://www.abstractsonline.com/pp8/#!/9325/presentation/2449Synopsis:Pro-apoptotic “initiators” (Noxa, Bim, Puma), anti-apoptotic “guardians” (Bcl-2, Mcl-1, Bcl-xL), and pro-apoptotic effectors (Bax/Bak) are all members of the Bcl-2 family of proteins. Venetoclax, a Bcl-2 receptor, has been approved by the Food and Drug Administration for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia. Venetoclax, on the other hand, is only moderately successful…

Dino Mehic, MD from the Medical University of Vienna speaks about Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency.Link to Abstract:https://ashpublications.org/bloodadvances/article/5/2/391/474924/Elevated-levels-of-tissue-factor-pathway-inhibitorPoints to Remember -* TFPI levels are higher in patients with minor bleeding disorders, especially those that have BUC or PFDs.* There were no genetic changes in the F5 gene that were related to increased TFPI levels.Synopsis:High levels of tissue factor pathway inhibitor (TFPI) were recently discovered in two families with an unknown bleeding propensity, due to a longer TFPI half-life after binding to a factor V splice variant and variations in the…

Frederick L. Locke, MD from H. Lee Moffitt Cancer Center and Research Institute speaks about the Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.Link to Article:https://jitc.bmj.com/content/8/2/e001511#ref-88SummaryIn a large number of patients with hematological tumors, immune effector cell (IEC) therapies have long-term remissions. Although these novel immunotherapies have increased results for children and adults in a variety of diseases, their toxicity profiles, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), vary significantly from that of traditional cancer therapies. At the time of writing, the US Food and Drug Administration…

Rona Yaeger, MD from Memorial Sloan Kettering Cancer Center speaks about KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Link to Article:https://www.nejm.org/doi/full/10.1056/NEJMoa1917239?query=featured_homeSummaryBEGINNINGSThere are no accepted cancer therapies that target KRAS mutations. The KRAS p.G12C mutation is found in 13% of non-small-cell lung cancers (NSCLCs) and 1–3% of colorectal cancers and other cancers. Sotorasib is a small molecule that targets KRASG12C in an irreversible and selective manner.APPROACHESIn patients with advanced solid tumors harboring the KRAS p.G12C mutation, we performed a phase 1 trial of sotorasib. Sotorasib was given orally once a day to the patients. The main goal was to ensure that…

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19. In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the discussion is surrounding Covid 19 variants and the challenge for cancer care. Thanks to Exelixis and Merck for their support of this program. For more, please…

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19 In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the doctors discuss what patients should expect post COVID19 vaccinations. Thanks to Exelixis and Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To…

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19. In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the discussion is surrounding whether the COVID19 vaccine is safe for cancer patients. Thanks to Exelixis and Merck for their support of this program. For more, please…

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19. In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the discussion is surrounding the continued use of telemedicine in cancer treatment. Thanks to Exelixis and Merck for their support of this program. For more, please visit…

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19. In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the discussion is surrounding changes and challenges of consistent cancer care during the pandemic. For more, please visit http://cancerGRACE.org/​. To join the conversation, visit https://cancergrace.org/forum​.

In this video series, presented in March of 2021, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19. In this continued time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this video the discussion is surrounding trends and implications – the COVID-19 pandemic and it’s continued impact on cancer care. For more, please visit http://cancerGRACE.org/​. To join the conversation,…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR Breakout Session, Drs. Jared…

For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer. Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at…

For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer. Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at…

For this years Case Based Panel Discussions – Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer. Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. Dr. Levy sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR…

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the EGFR…

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma. In this video, Dr. Postow discusses first line therapy for BRAF positive metastatic melanoma. A huge thank you to Merck for sponsoring this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma. In this video, Dr. Postow discusses understanding immunotherapy resistance mechanisms in melanoma. A huge thank you to Merck for sponsoring this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma. In this video, Dr. Postow discusses future prospects for immunotherapy agents in advanced melanoma. A huge thank you to Merck for sponsoring this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.